Gilead reported its first-quarterly PrEP milestone, with Yeztugo exceeding $1 billion in quarterly sales for the HIV prevention franchise. In the second quarter of 2026, PrEP sales reached $1.03 billion, with daily Descovy contributing $801 million, while Yeztugo generated $232 million. Despite the revenue beat, analysts are probing whether Yeztugo’s long-term growth can match the early adoption curve. Gilead kept its full-year Yeztugo forecast around $1 billion, and Leerink highlighted both favorable persistence early on and upcoming competitive risk from alternative formulations. The durability question also intersects with a future weekly oral lenacapavir-based PrEP option that is under FDA review, setting up a potential next phase of competition in a fragmented U.S. PrEP market.